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httcense.Abstract Background: Obstructive sleep apnea (OSA) causes chronic intermittent hypoxia (CIH)
during sleep. OSA is associated with nonalcoholic steatohepatitis (NASH) in obese individuals and
may contribute to progression of nonalcoholic fatty liver disease (NAFLD) from steatosis to steato-
hepatitis.
Objective: To assess the potential role of hypoxia in the development of NASH in obstructive
sleep apnea patients.
Methods: Nocturnal polysomnography was performed in 60 consecutive patients for clinical sus-
picion of OSA. We investigated fasting blood glucose, serum insulin, TNF-a, ABG and liver
enzymes for 30 patients with nocturnal polysomnographic recording of OSA and for 15 patients
without recording OSA used as controls. Liver biopsy was offered to 15 of 30 patients with elevated
liver enzymes.
Results: Patients with OSA had signiﬁcantly higher levels of insulin and were more insulin-resis-
tant according to HOMA-IR than in controls. We found that the parameters which signiﬁcantly
correlated with AHI were elevated liver enzyme, BMI, ultrasound grading, TNF-a and HOMA-
IR in patients group but did not ﬁnd a similar correlation in controls. Liver biopsy showed steatosis
with lobular necrosis or hepatocyte ballooning in the 15 patients, associated with ﬁbrosis in 5
patients.
Conclusion: Hypoxic stress of obstructive sleep apnea may be implicated in the evolution of insu-
lin resistance and steatohepatitis in obese individuals.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Obstructive sleep apnea (OSA) is a condition that affects 1–4%
of the general population and 25–35% of obese individuals [1].
According to the criteria deﬁned by the American Academy of
Sleep Medicine (AASM), OSA is a medical condition present-
ing the various symptoms caused by excessive day time
sleepiness (EDS) and obstructive sleep apnea (OSA) with anis. Production and hosting by Elsevier B.V.
10.027
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sleep apnea (OSA) is a complex disorder that consists of upper
airway obstruction, chronic intermittent hypoxia and sleep
fragmentation. OSA is well known to be associated with hy-
poxia, insulin resistance and glucose intolerance, and these fac-
tors can occur in the presence or absence of obesity and
metabolic syndrome [1,3]. Obstructive sleep apnea (OSA)
causes chronic intermittent hypoxia (CIH) during sleep.
Importantly, and potentially relevant to OSA, hypoxia is
now considered as one of the aggravating factors for develop-
ment of NAFLD [4], and interestingly, OSA is also regarded as
one of the factors that accelerate the progression of NAFLD
from steatosis to nonalcoholic steatohepatitis (NASH) [5].
NAFLD is emerging as an important public health problem
across the globe [6]. NAFLD refers to a wide spectrum of liver
damage, which ranges from simple steatosis to steatohepatitis,
advanced ﬁbrosis, and cirrhosis. NAFLD is strongly associ-
ated with insulin resistance and is deﬁned by accumulation
of liver fat >5% per liver weight, in the presence of <10 g dai-
ly alcohol consumption [7]. The diagnosis of NAFLD can be
established by ultrasound and can be conﬁrmed by liver
biopsy. The characteristic histology of NAFLD resembles that
of alcohol-induced liver injury, but occurs in people who con-
sume minimal or no alcohol. NAFLD is regarded as the most
common cause of elevated liver enzymes and is associated with
type 2 diabetes, obesity and hyperlipidemia [8].
In routine clinical practice, most cases of fatty liver disease
are attributable to alcohol excess; however, fatty liver disease
can also occur in association with a wide range of toxins,
drugs, and diseases, such as morbid obesity, cachexia, type 2
diabetes, hyperlipidemia, and after jejuno-ileal bypass surgery.
As important risk factors for NAFLD such as obesity and type
2 diabetes are increasing in prevalence this could explain the
marked increase in numbers of individuals with NAFLD [9].
We aimed from this study to assess the potential effect of
chronic intermittent hypoxia on the progression of hepatic ste-
atosis into non alcoholic steatohepatitis (NASH).
Patients and methods
Patients
The patients included in this study were referred to sleep unit
in Al Rashd Allergy center, Between December 2009 and Au-
gust 2010, with clinical suspicion of obstructive sleep apnea
(OSA) and without known liver diseases. Subjects with a his-
tory of excessive alcohol use, decompensate cardiac or respira-
tory insufﬁciency, treatment for OSA, regular use of
hepatotoxic drugs and known liver disease (e.g. chronic hepa-
titis C, B or autoimmune hepatitis ect.) were excluded.
Polysomnography
Level III sleep study applied on all patients which records na-
sal airﬂow (nasal cannulae) and oral airﬂow (thermistor), rib
cage and abdominal wall motion and arterial oxygen satura-
tion (SaO2). Sleep analysis was performed according to stan-
dard criteria [2]. The following data were recorded at the
time of polysomnography: age, sex, body mass index (BMI),
history of diabetes, hypertriglyceridemia, or high blood pres-
sure. Overweight was deﬁned as a BMI higher than 25 kg/
m2. All patients underwent a full-night sleep study tocharacterize their sleep and breathing patterns. Standard crite-
ria were employed to evaluate the breathing patterns during
sleep. Apnea was deﬁned as cessation of oronasal airﬂow for
10 s or more. Hypopnea was deﬁned as a reduction of oronasal
airﬂow, with a more than 4% fall in SaO2. The number of ap-
nea and hypopnea episodes per hour of sleep, or apnea hypo-
pnea index (AHI), was calculated. OSA was deﬁned as severe
when the AHI was above 30/hr, moderate when it was 15–30/
hr, and mild when it was from 5 to 10/hr and normal when less
than 5/hr [10,16].
Laboratory investigations
Immediately after the termination of the sleep study at 7 A.M.,
fasting venous blood samples were collected for liver function
test, glucose, insulin, lipid proﬁle and also arterial blood gas
(ABG) was measured. Insulin resistance was calculated via
homeostasis model assessment (HOMA) as follows: fasting
serum insulin · fasting serum glucose/22.5, where insulin is ex-
pressed in mU/L and glucose in lmol/L [11].
Patients with elevated liver enzymes were proposed for
additional laboratory investigations at the time of liver biopsy.
The following chronic liver diseases were excluded by using the
appropriate tests: hepatitis B, hepatitis C, autoimmune
hepatitis.
Ultrasonography
All patients included in the study underwent abdominal ultra-
sonography for exclusion of liver cirrhosis, ascites, focal lesion,
splenomegaly and renal abnormality, and also for determina-
tion of bright echo-pattern grading which correlated with the
degree of fatty inﬁltration of liver. Grade I (mild): Echogenicity
is slightly increased with normal visualization of the dia-
phragm and the intrahepatic vessels borders. Grade II (moder-
ate): Echogenicity is moderately increased with slightly
impaired visualization of the diaphragm or the intrahepatic
vessels borders. Grade III (severe): Echogenicity is markedly
increased with poor or no visualization of the diaphragm,
the intrahepatic vessels borders and posterior border of the
right lobe [33].
Liver biopsy
A liver biopsy was performed for histopathologic analysis after
taking a speciﬁc written informed consent.Pathology
Liver biopsy was proposed to patients with elevated liver en-
zymes. Liver biopsy was scored according to Brunt et al., with
modiﬁcations [34]. Steatosis was graded as follows: mild
(10–30% of hepatocytes affected), moderate (30–60% of hepa-
tocytes affected), and severe (60% of hepatocytes affected).
Fibrosis was graded on a scale of 0 to 4 (0, absent; 1, perisinu-
soidal/pericellular ﬁbrosis; 2, periportal ﬁbrosis; 3, bridging
ﬁbrosis; 4, cirrhosis). Intralobular necrosis was graded on a
scale of 0 to 3 (0, absent; 1, less than one necrosis injury per
lobule; 2, one or more necrosis injury per lobule; 3, more than
two necrosis injuries per lobule). Hepatocyte ballooning was
graded on a scale of 0 to 2 (0, absent; 1, ballooned hepatocytes
in less than 50% of lobules; 2, ballooned hepatocytes in more
than 50% of lobules). Nonalcoholic steatohepatitis (NASH)
was deﬁned by the presence of steatosis associated with lobular






Age 41.0 ± 8.25 39.3 ± 6.82 0.67 0.5
BMI 31.2 ± 3.74 26.8 ± 1.74 4.27 0.000
ALT 154.3 ± 20.5 51.5 ± 7.4 18.6 0.000
AST 128.6 ± 25.6 33.5 ± 5.4 14.1 0.000
Cholesterol 5.36 ± 0.8 3.82 ± 0.58 6.6 0.000
FBS 6.08 ± 1.29 5.12 ± 0.58 2.7 0.01
FSI 13.08 ± 7.1 10.19 ± 3.58 1.47 0.14
HOMA-IR 3.56 ± 2.08 2.38 ± 1.06 2.04 0.04
AHI 40.7 ± 12.4 10.07 ± 2.6 9.38 0.000
SPO2 83.0 ± 8.2 95.6 ± 1.76 5.8 0.000
The effect of chronic intermittent hypoxia in the evolution of NASH 199necrosis (grade 1 or more) or hepatocyte ballooning (grade 1
or more), with or without ﬁbrosis (grade 1 or more) [34].
Statistical analysis
The data was analyzed using the statistical package for social
sciences (spss) version 8.0 software. The signiﬁcance of differ-
ences between mean values of the study variables was evalu-
ated by using t-test. The signiﬁcance of differences between
proportions was performed using the Chi-square test. Correla-
tion coefﬁcient (r) between quantitative variables was calcu-
lated. The P value less than 0.05 is considered signiﬁcant.
Results
Nocturnal polysomnography was performed in 60 consecutive
patients for clinical suspicion of OSA. Fifteen patients were ex-
cluded: 3 because of known hepatitis B and C, 2 because use of
hepatotoxic drugs (e.g., rifampicin and nonsteroidal anti-
inﬂammatory drugs), and 10 because of incomplete data.
Therefore, 45 patients were included in the study: 30 of 45 pa-
tients had OSA with mean AHI of 40.7 and mean Spo2 of 83
and were used as patients group. 15 of 45 patients did not have
OSA with mean AHI of 10.07 and mean Spo2 of 95.6 and were
used as control group (Table 2).
Of these, 20 (66.6%) patients were females and 10 (33.4%)
patients were males in patient group, varying in age from
24 years to 53 years with the mean age of 41 years compared
with 9 (60%) females and 6 (40%) males in control group,
varying in age from 29 years to 51 years with the mean age
39.3 years (Table 2). BMI was signiﬁcantly higher in patients
group than in controls (Table 2). We observed a positive cor-
relation between BMI and AHI in patients group but did not
ﬁnd a similar correlation in controls (Table 1). Patients with
OSA had signiﬁcantly higher levels of insulin and were more
insulin-resistant according to HOMA-IR than in controls (Ta-
ble 2). There was relationship observed between AHI and the
level of insulin resistance as assessed by HOMA index in pa-
tients group (Table 1). HOMA-IR was signiﬁcantly correlated
with BMI in patients group (r= 0.39; p= 0.03).
Patients group exhibited elevated levels of liver enzymes




Age 0.06 0.7 0.2
BMI 0.40 0.02* 0.26
ALT 0.44 0.01* 0.11
AST 0.40 0.02* 0.18
TNF 0.39 0.03* 0.36
Cholesterol 0.12 0.5 0.12
FBS 0.04 0.82 0.04
FSI 0.03 0.8 0.12
HOMA-IR 0.46 0.01* 0.13
Abd. U/S grading 0.39 0.03* 0.09
Spo2 0.02 0.88 1
AHI 1 0 0.02protein, and albumin. We found that liver enzymes were signif-
icantly higher in patients group than in controls (Table 2). The
parameters which signiﬁcantly correlated with elevated liver
enzyme were AHI (Table 1) and TNFa (ALT, r= 0.4;
p= 0.02 and AST, r= 0.38; p= 0.03).
Liver biopsy was performed in 15 of 30 patients with ele-
vated liver enzymes. 11 of 15 patients had severe OSA (AHI)
and 4 of 15 patients had moderate OSA. Liver biopsy showed
steatosis in the 15 patients: mild in one patient, moderate in
nine patients, and severe in ﬁve patients. Steatosis was associ-
ated with lobular necrosis or hepatocyte ballooning in the 15
patients, deﬁning necro-inﬂammatory activity (steatohepatitis)
according to Brunt grading [34]. Among the 15 patients with
steatohepatitis, perisinusoidal ﬁbrosis was present in 5 patients
especially in those had severe OSA. Regarding histological
ﬁndings, The percentage of steatosis, Brunt grades (necro-
inﬂammatory activity) and Brunt stages (ﬁbrosis) were posi-
tively associated with AHI (r= 0.715; P= 0.001 and
r= 0.65, P= 0.01 and r= 0.46; P= 0.05, respectively).
There were no signiﬁcant differences as regard any of the his-
topathological ﬁndings between patients with severe OSA and
patients with moderate OSA.
In this research, we observed that grad III of ultrasonogra-
phy was the most common ﬁnding in patient group and grad I
was the most common in control group (Table 3). We observed
a positive correlation between ultrasonography grades and
AHI in patients group (r= 0.39; P= 0.03) but did not ﬁndemical parameters in studied groups.
Control group
AHI Spo2
p r p r p
0.18 0.01 0.95 0.42 0.11
0.33 0.19 0.48 0.41 0.12
0.55 0.25 0.36 0.46 0.08
0.32 0.13 0.62 0.01 0.95
0.04* 0.2 0.4 0.46 0.08
0.51 0.14 0.6 0.12 0.65
0.82 0.45 0.09 0.01 0.95
0.51 0.2 0.46 0.24 0.38
0.47 0.23 0.41 0.21 0.43
0.61 0.19 0.49 0.07 0.78
0 0.21 0.44 1 0
0.88 1 0 0.21 0.44
Table 3 Grading of ultrasonography in studied groups.







N % N % N %
Patients group 6 20.0 9 30.0 15 50.0
Control group 6 60.0 5 33.3 1 6.7
X2 7.2 Fisher exact 8.2
P value 0.007* 1.0 0.004*
200 A.A. El-Azeem I., M.A. Sarayaa similar correlation in controls (r= 0.19; P= 0.49). Simi-
larly, we found a positive correlation between ultrasonography
grades and HOMA-IR in patients group but not in control
group (Table 4). BMI was positively correlated with ultraso-
nography grades in both groups (Table 4). No correlation
was observed between ultrasonography grades and liver en-
zymes in both groups (as shown in Table 4).
TNF-a was positively correlated with AHI and negatively
correlated with Spo2 in patients groups but these correlations
were not observed in controls (as shown in Table 1).
Discussion
Nonalcoholic fatty liver disease (NAFLD) is a wide patholog-
ical complex ranging from simple steatosis to steatohepatitis,
advanced ﬁbrosis, cirrhosis and hepatocellular carcinoma
[12]. Nonalcoholic steatohepatitis (NASH) is considered to
be the cornerstone of NAFLD, showing abnormal triglyceride
deposition in hepatocytes along with acute and chronic lobular
and portal inﬂammation [13]. Experimental intermittent hy-
poxia (IH) has been shown to induce NASH [14]. The meta-
bolic disorders that predispose patients to NASH include
insulin resistance and obesity but the mechanism by which re-
peated hypoxic events, such as occur in OSA, can lead to the
progression of liver disease is unclear. This study assesses the
relationship between the presence of OSA and liver injury in
patients with steatosis and we try to clarify the mechanism
by which OSA induce NASH.
Insulin resistance is thought to be the ‘‘ﬁrst hit’’ in nonalco-
holic fatty liver disease, leading to excess free fatty acid accu-
mulation in the liver [15]. In our study, we found a signiﬁcant
link between insulin resistance and OSA, dependent of BMI.
This could be explained by the fact that OSA patients included
in this study have BMI more than 27, and BMI was positive
correlated with OSA and IR. This result suggests that obesityTable 4 Correlation between grading of ultrasonography and
some biochemical parameters in studied groups.
Items Grading of ultrasonography
Patients group Control group
r p r p
BMI 0.799 0.001* 0.515 0.05*
ALT 0.072 0.704 0.056 0.842
AST 0.134 0.48 0.097 0.73
HOMA-IR 0.41 0.02* 0.24 0.35
AHI 0.39 0.03* 0.19 0.49
SPO2 0.09 0.61 0.07 0.78is considered as a risk factor for OSA and IR, conﬁrming pre-
vious published studies [16,17]. Our data revealed that noctur-
nal chronic intermittent hypoxia (CIH) in obese individuals
with OSA were associated with marked increase in pro-inﬂam-
matory cytokine TNF-a. TNF-a is known to play a role in the
pathogenesis of insulin resistance [18]. Furthermore, abnormal
nocturnal sympathetic output has been proposed as the medi-
ating mechanism in the causal link between insulin resistance
and OSA [19]. Adipose tissue hypoxia (ATH) is a new concept
in understanding the pathogenesis of insulin resistance and
inﬂammation in OSA. The concept suggests that hypoxia stim-
ulate lipolysis, inhibit uptake of free fatty acid (FFA) in adipo-
cytes, and inhibit adipogenesis and triglyceride synthesis,
which leads to FFA elevation in the plasma of obese subjects
[1]. Recent data indicate that high plasma FFA have a signif-
icant role in contributing to insulin resistance [20]. Improve-
ment in insulin responsiveness after continuous positive
airway pressure treatment (CPAP) was reported [16]. There-
fore, it could be postulated that OSA contributes to increased
insulin resistance and steatosis.
In clinical practice, detection of liver injury is based on
abnormal liver tests, and liver biopsy is usually proposed only
for patients with elevated liver enzymes. In our study, the diag-
nosis of NASH was based on elevated liver enzymes, exclusion
of other causes of chronic liver disease ‘‘most notably viral
hepatitis and autoimmune hepatitis’’ and liver biopsy. As ex-
pected, liver biopsy revealed steatosis in all patients that asso-
ciated with hepatocyte ballooning or lobular necrosis, allowing
the diagnosis of NASH in 15 cases, associated with ﬁbrosis in 5
cases [12,21]. In our study, detection of liver damage was prob-
ably underestimated because diagnosis was based on elevated
liver enzymes, whereas cases of NASH without abnormal liver
tests have been reported [22]. In this study, OSA was signiﬁ-
cantly correlated with elevated liver enzymes. This ﬁnding
has been endorsed by other human studies which have shown
that OSA is associated with an increase in liver enzymes, and
treatment of OSA with continuous positive airway pressure
(CPAP) therapy has been shown to decrease liver enzymes
(ALT and AST) [1,23].
Progression of hepatic steatosis into NASH has been linked
to oxidative stress through lipid peroxidation, however,
accurate understanding of the trigger of inﬂammation in the
so-called ‘‘second hit’’ remain unclear [24]. The relationship
between AHI and lobular necrosis, hepatocyte ballooning
and liver ﬁbrosis in our biopsied patients suggests that OSA
may play a role in the pathogenesis of NASH. A possible
mechanism may be CYP2E1 activation which is a major
microsomal source of oxidative stress, as recently shown by
Chalasani et al., who found a signiﬁcant correlation between
hepatic CYP2E1 activity, nocturnal hypoxia, and serum insu-
lin levels in non-diabetic patients with biopsy-proven NASH
[25]. Liver injury in OSA could also be the result of direct hy-
poxia, as suggested in two previous case reports [16].
The previous experimental studies in the mouse model
showed that CIH increases lipid peroxidation and activates a
redox-dependent transcription factor, NF-kB, in the liver
[26]. NF-kB is the master regulator of inﬂammatory process
and its activation with hypoxia leads to activation of TNF-a,
IL-1, IL-6, monocyte chemoattractant protein-1, macrophage
migration-inhibition factor and inducible nitric oxide synthase
[27,28]. Importantly, NF-kB is also increased not only with
OSA but also with obesity and metabolic syndrome [27]. It
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pro-inﬂammatory cytokines IL-1b, IL-6, macrophage inﬂam-
matory protein-2, and TNF-a [29]. Our present report and pre-
vious experimental data suggest that the hypoxic stress of OSA
may induce oxidative stress in the livers of patients with severe
obesity, leading to inﬂammation and ﬁbrosis, which culminate
in NASH [30].
Increase in plasma leptin level is considered another possi-
ble mechanism by which OSA could induce the progression of
hepatic steatosis to steatohepatitis. Leptin is a hormone that is
secreted by adipose tissue and increases with obesity. The main
role of leptin is to reduce appetite [31]. OSA is known to be
associated with an increase in plasma leptin levels, and the in-
crease in leptin occurs in proportion to the severity of OSA
[31]. Increased leptin is known to be associated with NAFLD
[32].
Conclusion
Our ﬁndings suggest that the hypoxic stress of OSA could play
a role in the pathogenesis of increasing insulin resistance and
the progression of hepatic steatosis to steatohepatitis in obese
individuals. Histo-pathological evidence from 15 obese indi-
viduals has shown that OSA is associated with NASH. In addi-
tion, we have shown that OSA is a risk factor for abnormal
liver enzymes and should be investigated in patients without
other cause of liver disease. Future studies are needed to eluci-
date whether treatment of OSA with CPAP can improve liver
injury or not.
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